ASX Stocks Estimated To Be Trading Below Fair Value In August 2026
As the Australian market grapples with the implications of rising oil prices and their potential inflation impacts, investors are increasingly looking for opportunities within sectors that may be trading below their intrinsic value. In such a climate, identifying undervalued stocks can be particularly advantageous, as these investments often offer significant potential for growth when broader market conditions stabilize.
Top 10 Undervalued Stocks Based On Cash Flows In Australia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Xero (ASX:XRO) | A$82.75 | A$145.14 | 43% |
| Symal Group (ASX:SYL) | A$2.82 | A$5.50 | 48.7% |
| Superloop (ASX:SLC) | A$3.12 | A$5.61 | 44.4% |
| PolyNovo (ASX:PNV) | A$1.055 | A$1.96 | 46% |
| Nuix (ASX:NXL) | A$1.49 | A$2.68 | 44.3% |
| NRW Holdings (ASX:NWH) | A$7.09 | A$13.54 | 47.7% |
| Navigator Global Investments (ASX:NGI) | A$2.61 | A$4.49 | 41.8% |
| Mesoblast (ASX:MSB) | A$2.40 | A$4.24 | 43.4% |
| Genesis Minerals (ASX:GMD) | A$7.33 | A$14.21 | 48.4% |
| Frontier Digital Ventures (ASX:FDV) | A$0.32 | A$0.64 | 49.8% |
Below we spotlight a couple of our favorites from our exclusive screener.
Cochlear (ASX:COH)
Overview: Cochlear Limited offers implantable hearing solutions across the Americas, Europe, the Middle East, Africa, and Asia Pacific with a market cap of A$9.23 billion.
Operations: Cochlear generates revenue from implantable hearing solutions across various regions, including the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Estimated Discount To Fair Value: 38.5%
Cochlear is trading at A$141.2, significantly below its estimated future cash flow value of A$229.61, indicating potential undervaluation based on cash flows. Despite a drop in net income to A$147.3 million and lower profit margins compared to last year, earnings are forecasted to grow at 22.1% annually, outpacing the Australian market average of 11.8%. However, revenue growth is expected to be slower than the market average, and dividends are not well covered by earnings or free cash flows.
- Our earnings growth report unveils the potential for significant increases in Cochlear's future results.
- Click to explore a detailed breakdown of our findings in Cochlear's balance sheet health report.
PolyNovo (ASX:PNV)
Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across several countries including Australia, New Zealand, and the United States, with a market cap of A$728.84 million.
Operations: The company's revenue primarily comes from the development, manufacturing, and commercialization of NovoSorb Technology, generating A$139.49 million.
Estimated Discount To Fair Value: 46%
PolyNovo is trading at A$1.06, considerably below its estimated future cash flow value of A$1.96, highlighting potential undervaluation based on cash flows. Revenue is expected to grow at 10.7% annually, outpacing the Australian market's 6%, while earnings are forecasted to increase significantly by 29.7% per year over the next three years. Despite these positive growth projections, PolyNovo's return on equity is anticipated to remain relatively low at 18.3%.
- In light of our recent growth report, it seems possible that PolyNovo's financial performance will exceed current levels.
- Take a closer look at PolyNovo's balance sheet health here in our report.
Symal Group (ASX:SYL)
Overview: Symal Group Limited operates in the civil construction industry in Australia, offering services such as construction contracting, equipment hires, material sales, recycling, and remediation with a market cap of A$674.39 million.
Operations: Symal Group Limited generates revenue from its segments with A$801.43 million coming from contracting services and A$187.79 million from plant and equipment.
Estimated Discount To Fair Value: 48.7%
Symal Group is trading at A$2.82, significantly below its estimated future cash flow value of A$5.5, suggesting it is undervalued based on cash flows. The company's revenue growth forecast of 17.9% annually surpasses the Australian market average of 6%, and earnings are projected to grow at 14.2% per year. Analysts expect a stock price increase of 25.5%. Recent M&A activities may impact future performance positively or negatively, depending on integration success.
- According our earnings growth report, there's an indication that Symal Group might be ready to expand.
- Click here and access our complete balance sheet health report to understand the dynamics of Symal Group.
Where To Now?
- Unlock our comprehensive list of 48 Undervalued ASX Stocks Based On Cash Flows by clicking here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com